REDWOOD CITY, Calif.,
Nov. 29, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),
a specialty pharmaceutical company focused on the development
and commercialization of innovative therapies for use in medically
supervised settings, today announced that it will host an analyst
and investor day on Tuesday, December 11,
2018 from 8:30 a.m. ET to 11:00 a.m.
ET in New York City.
AcelRx management will discuss the Company's U.S.
commercialization strategy and market opportunity for DSUVIA™.
The event will also feature a presentation by Dr.
Eugene Viscusi, Chief of Pain
Medicine at Thomas Jefferson
University, and a panel discussion with Dr. Louis Guzzi, Anesthesiologist and Director of
the Intensive Care Unit at Florida Hospital Waterman, Dr.
Jasmine Jones, Clinical Pharmacy
Pain Specialist at WellStar Kennestone Hospital, Dr. Michael Ritter, Medical Director, Emergency
Department at St. Joseph Mission Hospital and CHOC Children's
Hospital, and Jean Tersteeg, Nurse
Team Lead at Hennepin County Medical Center.
Institutional investors and analysts who would like to attend
the event, please contact acelrxevents@troutgroup.com.
A live webcast of the event, with accompanying slides, will be
accessible by visiting the Investors section of the company's
website at www.acelrx.com. A replay of the webcast will also
be available and archived on the site.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and one product candidate,
Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg)
being developed as an innovatively designed patient-controlled
analgesia (PCA) system for reduction of moderate-to-severe acute
pain in medically supervised settings. DZUVEO and Zalviso are both
approved products in Europe. For additional information
about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-host-analyst-and-investor-day-on-december-11-300757949.html
SOURCE AcelRx Pharmaceuticals, Inc.